Retatrutide Achieves 2.0% A1C Reduction and 16.8% Weight Loss in Phase 3 TRANSCEND-T2D-1 Trial

Bottom line: Retatrutide's triple-agonist mechanism delivers the deepest A1C cut and the most weight loss ever seen in a Phase 3 diabetes trial, with no weight-loss plateau at 40 weeks — positioning it as a potential best-in-class metabolic therapy.

Retatrutide (LY3437943) is an investigational first-in-class peptide that simultaneously activates three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple-agonist approach is designed to improve glycemic control while maximizing weight loss through complementary metabolic pathways.

On March 19, 2026, Eli Lilly announced positive topline results from TRANSCEND-T2D-1 (NCT06354660), the first Phase 3 trial evaluating retatrutide specifically in adults with type 2 diabetes who had inadequate glycemic control with diet and exercise alone.¹

Key Findings

At 40 weeks, the highest dose of retatrutide (12 mg once weekly) achieved:

• HbA1c reduction: −2.0 percentage points from baseline (vs. placebo)
• Body weight reduction: 16.8% from baseline
• No apparent weight-loss plateau at study end, suggesting further losses may accrue with longer treatment
• All primary and key secondary endpoints were met with statistical significance

The safety profile was consistent with the GLP-1 receptor agonist class. Gastrointestinal events (nausea, diarrhea, vomiting) were the most common adverse effects, mostly mild to moderate and occurring during dose escalation.

Context Within the Pipeline

The TRANSCEND-T2D-1 results complement the previously reported TRIUMPH-4 obesity data, where retatrutide achieved 28.7% weight loss in adults without diabetes. Together, these trials establish retatrutide as a potential best-in-class agent for both diabetes and obesity.

For comparison:

• Semaglutide 2.4 mg achieves ~6–7% weight loss in T2D populations (STEP-2)
• Tirzepatide 15 mg achieves up to 12.8% weight loss in T2D (SURPASS-3)
• Retatrutide 12 mg achieved 16.8% at only 40 weeks, with trajectory still descending

Clinical Implication

If the full TRANSCEND program confirms these results, retatrutide could redefine treatment targets in type 2 diabetes — making double-digit weight loss a standard expectation alongside near-normalization of HbA1c. Prescribers currently managing patients on tirzepatide or semaglutide who plateau short of glycemic or weight targets should monitor this pipeline closely.

---

¹ Eli Lilly and Company. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Press release, March 19, 2026. investor.lilly.com